Literature DB >> 15933055

Natural-killer cells and dendritic cells: "l'union fait la force".

Thierry Walzer1, Marc Dalod, Scott H Robbins, Laurence Zitvogel, Eric Vivier.   

Abstract

Several recent publications have focused on the newly described interactions between natural-killer (NK) cells and dendritic cells (DCs). Activated NK cells induce DC maturation either directly or in synergy with suboptimal levels of microbial signals. Immature DCs appear susceptible to autologous NK-cell-mediated cytolysis while mature DCs are protected. NK-cell-induced DC activation is dependent on both tumor necrosis factor-alpha (TNF-alpha)/interferon-gamma (IFN-gamma) secretion and a cell-cell contact involving NKp30. In vitro, interleukin-12 (IL-12)/IL-18, IL-15, and IFN-alpha/beta production by activated DCs enhance, in turn, NK-cell IFN-gamma production, proliferation, and cytotoxic potential, respectively. In vivo, NK-cell/DC interactions may occur in lymphoid organs as well as in nonlymphoid tissues, and their consequences are multiple. By inducing DC activation, NK-cell activation induced by tumor cells can indirectly promote antitumoral T-cell responses. Reciprocally, DCs activated through Toll-like receptors (TLRs) induce potent NK-cell activation in antiviral responses. Thus, DCs and NK cells are equipped with complementary sets of receptors that allow the recognition of various pathogenic agents, emphasizing the role of NK-cell/DC crosstalk in the coordination of innate and adaptive immune responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15933055     DOI: 10.1182/blood-2005-03-1154

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  213 in total

1.  Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity.

Authors:  Philipp A Lang; Karl S Lang; Haifeng C Xu; Melanie Grusdat; Ian A Parish; Mike Recher; Alisha R Elford; Salim Dhanji; Namir Shaabani; Charles W Tran; Dilan Dissanayake; Ramtin Rahbar; Magar Ghazarian; Anne Brüstle; Jason Fine; Peter Chen; Casey T Weaver; Christoph Klose; Andreas Diefenbach; Dieter Häussinger; James R Carlyle; Susan M Kaech; Tak W Mak; Pamela S Ohashi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-13       Impact factor: 11.205

2.  Clusterin synergizes with IL-2 for the expansion and IFN-γ production of natural killer cells.

Authors:  Chung Hee Sonn; Young-Bin Yu; Young-Joo Hong; Young-Jun Shim; Jeffrey A Bluestone; Bon-Hong Min; Kyung-Mi Lee
Journal:  J Leukoc Biol       Date:  2010-08-20       Impact factor: 4.962

3.  TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.

Authors:  Mitsuhiro Iyori; Tong Zhang; Haddon Pantel; Bethany A Gagne; Charles L Sentman
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

4.  IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.

Authors:  B Schilling; E S Halstead; P Schuler; M Harasymczuk; J E Egan; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2012-01-20       Impact factor: 6.968

5.  Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures.

Authors:  Helder I Nakaya; Thomas Hagan; Sai S Duraisingham; Eva K Lee; Marcin Kwissa; Nadine Rouphael; Daniela Frasca; Merril Gersten; Aneesh K Mehta; Renaud Gaujoux; Gui-Mei Li; Shakti Gupta; Rafi Ahmed; Mark J Mulligan; Shai Shen-Orr; Bonnie B Blomberg; Shankar Subramaniam; Bali Pulendran
Journal:  Immunity       Date:  2015-12-15       Impact factor: 31.745

6.  Rickettsiae stimulate dendritic cells through toll-like receptor 4, leading to enhanced NK cell activation in vivo.

Authors:  Jeffrey M Jordan; Michael E Woods; Lynn Soong; David H Walker
Journal:  J Infect Dis       Date:  2009-01-15       Impact factor: 5.226

Review 7.  Tetherin/BST-2: Restriction Factor or Immunomodulator?

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; Mario L Santiago
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

8.  TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity.

Authors:  Osman N Yogurtcu; Zuben E Sauna; Joseph R McGill; Million A Tegenge; Hong Yang
Journal:  AAPS J       Date:  2019-08-02       Impact factor: 4.009

Review 9.  Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions.

Authors:  Jeffery J Auletta; Kenneth R Cooke; Luis A Solchaga; Robert J Deans; Wouter van't Hof
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-16       Impact factor: 5.742

10.  Dendritic cells are required for optimal activation of natural killer functions following primary infection with herpes simplex virus type 1.

Authors:  Sadik H Kassim; Naveen K Rajasagi; Barry W Ritz; Stephen B Pruett; Elizabeth M Gardner; Robert Chervenak; Stephen R Jennings
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.